Intermittent androgen suppression

BJU International

Volumn 93, Issue 3, 2004, Pages 258-261

  Pether, M ^a   Goldenberg, S L ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Androgens; Intermittent therapy; Outcome; Prostate cancer; Survival

Indexed keywords

ANDROGEN;

CLINICAL EXAMINATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HORMONE ACTION; HORMONE DEPENDENCE; HUMAN; LABORATORY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY;

ANDROGEN ANTAGONISTS; ANIMALS; CELL DIVISION; CLINICAL TRIALS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 1342310058     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04597.x     Document Type: Short Survey

References (32)

1. Huggins CB, Hodges CV. Studies on prostate cancer: The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 203
2. Huggins C, Stephens RC, Hodges CV. Studies on prostate cancer: 2. The effect of castration on advanced carcinoma of the prostate. Arch Surg 1941; 43: 209
3. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72: 3888S-3895S
4. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostatic carcinoma. Cancer 1997; 79: 545-50
5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-4412
6. Bruchovsky N, Goldenberg SL, Rennie PS et al. Theoretical considerations and the initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma. Urologe (a) 1995; 34: 389-92
7. Bruchovsky N. Androgens and antiandrogens, In Holland JF, Frei E III, Bast RC et al. eds, Cancer Medicine, Fourth Edn. Baltimore: Williams & Wilkins, 1996: 1133-48
8. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. The Prostate 2002; 50: 179-88
9. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4
10. Foulds L. Neoplastic Development 1, New York: Academic Press 1969
11. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1977; 37: 82-94
12. Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987; 137: 785-8
13. Russo P, Liguori G, Heston WDW et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 1987; 47: 5967-70
14. Bruchovsky N, Rennie PS, Coldman AJ et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82
15. Akakura K, Bruchovsky N, Goldenberg SL et al. Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate specific antigen. Cancer 1993; 71: 2782-90
16. Gleave ME, Hsieh JT, Wu H-C et al. Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992; 52: 1598
17. Sato N, Gleave M, Bruchovsky N, Rennie P, Beraldi E, Sullivan L. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997; 57: 1584-9
18. Sato N, Gleave ME, Bruchovsky N, Goldenberg SL, Rennie P, Sullivan LD. Intermittent androgen suppression delays time to non-androgen regulated prostate specific antigen gene expression in the human prostate LNCaP tumour model. J Steroid Biochem Molec Biol 1996; 58: 139-46
19. Klotz LH, Herr HW, Morse MJ et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-60
20. MRC. Immediate versus deferred treatment for advanced prostatic cancer. Initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46
21. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. New England J Med 1998; 186: 63-74
22. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients. Factors predictive of prolonged time off therapy. Oncologist 2000; 5: 45-52
23. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Maximal biochemical and pathological downstaging requires 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy. J Urol 1996; 155: 213-9
24. Gleave ME, Goldenberg SL, Jones E, Bruchovsky N, Sullivan LD. Longer duration of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy in clinically localized prostate cancer: biochemical and pathological effects. Mol Urol 1997; 1: 199-204
25. Pether M, Goldenberg SL, Bhagirath K, Gleave ME. Intermittent androgen suppression in prostate cancer. An update of the Vancouver experience. Can J Urol 2003; 10: 1809-14
26. Higano CS, Ellis W, Russel K et al. Intermittent androgen suppression with leuprilide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800-4
27. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 530-4
28. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation. update of cycle characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001; 58: 240-5
29. Horwich A, Huddart RA, Gadd J et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96-9
30. Prapotnich D, Fizazi K, Escudier B et al. A 10 year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 233-40
31. Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
32. Anonymous. Determinants of prostate specific antigen (PSA) normalization for prostate cancer (PCa) patients (pts) registered to Southwest Oncology Group (SWOG) Study 9346 (INT-0162). ASCO 2003